Eton Pharmaceuticals, Inc. ETON Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s additional paid-in capital?
- Eton Pharmaceuticals, Inc. (ETON) reported additional paid-in capital of $141.53M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Eton Pharmaceuticals, Inc.'s additional paid-in capital increased by 5.7% year-over-year, from $133.89M to $141.53M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 5.2% compound annual growth rate (CAGR), from $107.8M to $138.62M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.